149. Effect of Lurasidone on Quality of Life, Function, and Metabolic Parameters in Adolescent Patients With Schizophrenia: Results From a 6-Week, Double-Blind, Placebo-Controlled Study

ABSTRACT: Abstract Background: Several atypical antipsychotics are approved to treat adolescent patients with schizophrenia. However, risk for antipsychotic-associated weight gain and metabolic dysfunction underscores the need to identify additional evidence-based treatments that are both efficacious and well tolerated in this vulnerable patient population. Lurasidone is an atypical antipsychotic agent that has demonstrated efficacy in the treatment of adults with schizophrenia in the dose range of 40–160 mg/d. The objective of this randomized, double-blind, placebo-controlled study was to evaluate the efficacy and safety of lurasidone in adolescent patients with schizophrenia. Methods: Adolescent patients (13–17 years old) who met DSM-IV-TR criteria for schizophrenia were randomized to 6 weeks of d

SUBMITTER: Findling R 

PROVIDER: S-EPMC5475665 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature